Carisoprodol
Viewing r1 — May 12, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Carisoprodol — Soma — is a synthetic depressant of the propanediol dicarbamate class. It is a structural relative of meprobamate, modified to deliver muscle relaxation with reduced abuse liability. It amplifies inhibitory GABA signaling in the brain — and can open GABA receptors directly without GABA present — producing sedation, anxiety relief, and muscle relaxation.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Synthesized in the early 1950s, carisoprodol was approved in 1959 as a purportedly safer successor to meprobamate.[2] That promise failed — documented abuse and fatal overdoses drove decades of progressive scheduling and market withdrawal. It remains available by prescription in the United States but has been withdrawn across Europe, and a 2025 UN decision now obligates global controls.[3]
Subjective effects include sedation, anxiolysis, muscle relaxation, dizziness, and psychomotor impairment. The experience is defined by a heavy, body-dominant calm that blankets motor control and thought simultaneously — more physically engulfing than benzodiazepine sedation.[4] Confusion and a dangerous gap between perceived and actual impairment are common unsought effects.
Carisoprodol produces rapid physical dependence, and the gap between a therapeutic and fatal blood concentration is narrow.[5] Its active metabolite meprobamate accumulates with repeated dosing and compounds both dependence and overdose risk; combining carisoprodol with opioids increases overdose risk by 84%.[6] Six decades of clinical and forensic data provide a substantial evidence base, though how carisoprodol affects serotonin — causing dangerous overheating reactions in some cases — remains unexplained.[7]
History[edit]
Discovery
Carisoprodol was synthesized by Frank M. Berger and Bernard J. Ludwig at Wallace Laboratories in the early 1950s.[2] It was a deliberate modification of meprobamate — Berger's earlier anxiolytic — with a single structural change designed to produce a muscle relaxant with lower abuse potential and greater overdose safety.
Clinical adoption and emerging abuse
Approved by the FDA in 1959 and marketed as Soma, carisoprodol was widely prescribed for acute musculoskeletal pain with limited scrutiny of its abuse liability. By the 1990s, case reports documented escalating abuse,[8] meprobamate dependence developing from chronic use,[9] and dose escalation consistent with tolerance.[10] Norwegian prescription data confirmed 15% of patients received doses consistent with dependence, strongly linked to concurrent benzodiazepine and opioid use.[11]
Scheduling and market withdrawal
Sweden withdrew carisoprodol in 1994; Norway rescheduled and withdrew it in 2007–2008;[12] the EU withdrew marketing authorization the same year. The US DEA placed it in Schedule IV in January 2012.[13] In 2025, the UN added it to Schedule IV of the Convention on Psychotropic Substances, obligating all member states to implement domestic controls.[3]
The brand name Soma — shared with the divine intoxicant of Vedic mythology and the pleasure drug of Aldous Huxley's Brave New World — gave carisoprodol cultural resonance beyond its pharmacological novelty. In street drug culture, it became synonymous with the "Holy Trinity" combination: carisoprodol with an opioid and a benzodiazepine, documented across US emergency departments and forensic reports.[14]
Chemistry[edit]
Structural class
Carisoprodol belongs to the propanediol dicarbamate family, sharing its core scaffold with meprobamate.[2] The only structural difference from meprobamate is a single isopropyl group added to one carbamate nitrogen — a minor modification that produces modestly different pharmacokinetics while preserving the same GABA receptor targets.
Molecular properties
Its molecular formula is C₁₂H₂₄N₂O₄ (molecular weight 260.33 g/mol). The molecule is an open-chain compound with no ring systems. Carisoprodol is a white crystalline powder, insoluble in water but freely soluble in alcohol and organic solvents.citation needed
Pharmacology[edit]
Mechanism of action
Carisoprodol acts on GABA receptors two ways. It amplifies existing GABA activity — like a benzodiazepine — and also directly opens the receptor's channel without GABA present, like a barbiturate.[1][15] At some receptors outside synapses, it activates the channel more powerfully than GABA itself — a property that likely explains its heavy sedation and abuse potential.[1]
Active metabolite
The liver converts carisoprodol into meprobamate, which is itself active at GABA receptors.[16] Meprobamate lasts around 10 hours in the body versus 2 hours for carisoprodol, so it accumulates with repeated doses and substantially compounds both effects and dependence.[16][17] People who process the drug slowly (CYP2C19 poor metabolizers) experience roughly four times the exposure at standard doses — a variation present in 15–20% of East Asian populations.[17][18]
Serotonergic activity
Cases of dangerous overheating, muscle rigidity, and agitation — consistent with excess serotonin in the brain — have been documented during carisoprodol use.[7][19] How carisoprodol affects serotonin is unknown: no receptor studies have confirmed the mechanism. This is a safety-critical pharmacological gap.
Neuroscience[edit]
Where it acts
Carisoprodol suppresses activity across multiple brain regions by activating GABA receptors. At receptors outside synapses — in the thalamus, cerebellum, and hippocampus — it drives inhibition beyond GABA's own capacity, generating pronounced psychomotor impairment even at therapeutic doses.[1][4] The relative sparing of certain brainstem receptors appears to explain delusions of sobriety — users test as substantially more impaired than they feel.[4]
Reward and dependence
Carisoprodol activates the brain's reward system by releasing dopamine in the brain's pleasure center. Combined with opioids, the dopamine surge is synergistic rather than additive.[14][11]
Chronic use reduces the number of active GABA receptors.[20] When the drug is stopped, the brain becomes hyperexcitable — producing anxiety, insomnia, and seizures — which drives compulsive redosing.
Key unknowns include the mechanism behind carisoprodol's serotonergic activity,[7][19] how metabolizer status shapes subjective experience and abuse liability, and whether super-agonist activity at extrasynaptic receptors is necessary for the reinforcement.[1] No data exist on whether carisoprodol produces lasting changes to brain structure.
Subjective Effects[edit]
Carisoprodol produces a heavy, body-dominant sedation that envelops motor control, cognition, and mood at once. The feeling is not simply strong relaxation — it is a wholesale suppression of arousal, with limbs growing heavy and thought losing urgency. The same character deepens with dose without shifting into qualitatively new territory.
Compared to benzodiazepines, carisoprodol produces greater physical weight and more pronounced psychomotor impairment relative to the subjective sense of intoxication. The closest comparison is its own metabolite meprobamate — though carisoprodol's faster onset creates a more acute, front-loaded experience before meprobamate's slower contribution extends the tail.
Effect Grid
Pronounced muscle relaxation, moderate sedation, and clear anxiolysis define this range. Thought deceleration becomes evident — cognitive processing slows perceptibly. Delusions of sobriety are characteristic: users feel less impaired than objective testing demonstrates.
Physical effects include noticeable motor control impairment, bodily heaviness, and dizziness. Tactile euphoria may emerge in some individuals. Pain suppression is moderate. Sedation dominates the physical profile without approaching incapacitation.
This encompasses the standard therapeutic range (325-500 mg). Driving and machinery operation are objectively impaired even when the user feels capable. Cognitive euphoria reported by some but not confirmed in controlled settings.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Vestibular distortion · Visual haze / noise · Visual processing suppression
Dizziness · Pain suppression · Bodily heaviness · Body high · Breathing alteration · Nausea · Sexual arousal suppression · Tactile euphoria · Dry mouth · Headache · Nystagmus (eye wobbles) · Vomiting
Breathing alteration · Nausea · Sexual arousal suppression · Tactile euphoria · Dry mouth · Headache · Nystagmus (eye wobbles) · Vomiting
Cognitive fatigue · Focus suppression · Information processing suppression · Language suppression · Pattern recognition suppression · Cognitive euphoria · Confusion · Creativity suppression · Memory suppression · Motivation suppression · Thought disorganization · Compulsive redosing urge · Delusions of sobriety · Memory fragmentation · Amnesia · Delirium
Language suppression · Pattern recognition suppression · Cognitive euphoria · Confusion · Creativity suppression · Memory suppression · Motivation suppression · Thought disorganization · Delusions of sobriety · Memory fragmentation · Amnesia · Delirium
Craving · Sociability suppression
Timeline
Initial awareness of subtle muscle relaxation and mild warmth. Sedation not yet prominent but a softening of baseline tension is perceptible.
Progressive sedation and anxiolysis develop. Motor relaxation deepens noticeably. Thought deceleration begins; a sense of physical heaviness emerges.
Full sedative-anxiolytic-myorelaxant state. Psychomotor impairment maximal. Carisoprodol Cmax reached; meprobamate levels still rising.
Carisoprodol levels declining; meprobamate sustains residual sedation and muscle relaxation. Motor function slowly recovers. Cognitive slowing persists.
Meprobamate-driven residual sedation and physical fatigue. Duration varies substantially by dose and CYP2C19 metabolizer status.
⚠ Do not drive or operate machinery for at least 8 hours after dosing — psychomotor impairment persists beyond subjective awareness of sedation.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- High
- Withdrawal
- Life-threateningfatal risk
- Tolerance buildup
- moderate
- Tolerance reset
- 30 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- Moderate
- Dose escalation
- High
- Cross-tol.
- benzodiazepines · barbiturates · alcohol
Toxicity
Acute toxicity
Carisoprodol has a narrow margin between therapeutic and fatal blood concentrations. Levels above 15 mg/L can be fatal alone, and in solo poisoning cases the median blood concentration at death was 36 mg/L.[21] Even at lower concentrations, it can contribute to death when combined with other depressants.[5]
Carisoprodol has a narrow margin between therapeutic and fatal concentrations, particularly in CYP2C19 poor metabolizers and when combined with other depressants. Respiratory depression is the primary lethal mechanism.
Polydrug overdose
Combining carisoprodol with opioids increases overdose risk by 84% (adjusted HR 1.84, 95% CI 1.34–2.54), with risk rising further after 60 days of combined use.[6][22] The "Holy Trinity" — carisoprodol with an opioid and a benzodiazepine — carries the highest mortality risk through synergistic breathing suppression.[14] Fatal outcomes have also been documented with GHB co-ingestion.[23]
Genetic vulnerability
People whose livers process carisoprodol slowly (CYP2C19 poor metabolizers) accumulate roughly four times the drug exposure at standard doses.[18] This variation has been directly linked to fatal poisonings at doses considered safe for the general population.[24]
Serotonin syndrome
Cases of dangerous overheating, muscle rigidity, and agitation — matching serotonin syndrome — have been documented during carisoprodol use.[7][19] The mechanism is unknown. Standard depressant-overdose care may be insufficient; treatment may require specific serotonin-blocking agents and active cooling.safety citation needed
Elderly population
Carisoprodol appears on the American Geriatrics Society Beers Criteria as potentially inappropriate for older adults due to fall risk and CNS adverse effects.citation needed
Psychological risks
At higher-than-prescribed doses, carisoprodol produces elevated mood, confusion, disorientation, and delusions.[3] Delusions of sobriety — feeling far less impaired than objective testing reveals — contribute to driving accidents and other harm.[4]
Stopping abruptly after prolonged high-dose use can produce hallucinations and delirium.[25] Even at the standard therapeutic dose, a measurable gap exists between perceived and actual psychomotor impairment.[4][12]
Tolerance and dependence
Tolerance
Tolerance develops through GABA downregulation, confirmed in animal models that also demonstrated physical dependence through precipitated withdrawal.[20] The pattern parallels tolerance seen with barbiturates and benzodiazepines.
Dependence
Physical and psychological dependence are well-documented:
- Meprobamate dependence developing from chronic carisoprodol use[9]
- Escalating abuse patterns with carisoprodol as the primary drug[8][10]
- Severe dependence after 14 years of continuous use[25]
- Documented abuse in North India as an underrecognized phenomenon[26]
- Norwegian data showing 15% of patients received doses consistent with tolerance and dependence, strongly linked to concurrent benzodiazepine and opioid use[11]
Withdrawal
Withdrawal brings anxiety, insomnia, restlessness, craving, and headache. Abrupt cessation after prolonged high-dose use can produce seizures, delusions, and hallucinations.[25] Withdrawal resembles barbiturate withdrawal and is potentially life-threatening in severe cases; management typically uses benzodiazepines, though severe cases may be treatment-resistant.[25]
Cross-tolerance
No published human data exist on cross-tolerance with other GABA-targeting drugs. By analogy with barbiturates, cross-tolerance with benzodiazepines, alcohol, and barbiturates is expected but unconfirmed. inferred
Drug interactions
CNS depressant synergy
Opioid co-administration increases overdose risk by 84% (adjusted HR 1.84, 95% CI 1.34–2.54), escalating with treatment duration.[6][22] Adding a benzodiazepine — the "Holy Trinity" — layers three mechanisms of breathing suppression.[14] Alcohol and GHB add further risk; at least one GHB co-ingestion fatality is documented.[23]
Serotonergic interactions
Caution is warranted with all serotonergic drugs — SSRIs, SNRIs, MAOIs, tramadol, and triptans — given documented serotonin syndrome cases.[7][19] A fatal case involving sumatriptan and carisoprodol has been reported.[27]
CYP2C19-mediated interactions
CYP2C19 inhibitors (omeprazole, fluoxetine, fluvoxamine) slow carisoprodol clearance and increase exposure. CYP2C19 inducers (rifampin, carbamazepine, St. John's Wort) speed conversion to meprobamate.[28][18] Fluoxetine is both a CYP2C19 inhibitor and a serotonergic agent — a dual-risk combination.
Contraindications
Absolute
- Known CYP2C19 poor metabolizer status: Standard doses produce approximately four-fold higher exposure, with documented fatal outcomes.[24][18] Alternative muscle relaxants should be used.
- Concurrent opioid therapy: HR 1.84 for overdose;[6] the risk-benefit ratio does not support co-prescription.
- History of meprobamate or carisoprodol hypersensitivity: Cross-reactivity expected given metabolic conversion.[28]
Relative
- Concurrent benzodiazepine or alcohol use: Additive respiratory and CNS depression.[14]
- Treatment duration exceeding 2–3 weeks: Dependence risk increases substantially with prolonged use.[28]
- Elderly patients: Fall risk and CNS adverse effects.citation needed
- Under 16 years: Safety and efficacy not established.[28]
- Pregnancy: No major birth defect risk identified, but formal safety studies are lacking.[28]
- Concurrent serotonergic agents: Serotonin syndrome documented.[7][19]
- CYP2C19 inhibitor co-administration: Mimics poor metabolizer phenotype.[18]
Harm Reduction[edit]
Forms & Identification
Carisoprodol is prescribed as oral tablets, typically 250 mg or 350 mg. Diverted prescription tablets may be genuine, but street formulations have appeared combining carisoprodol with other active substances — notably "red apple" tablets containing tapentadol, identified in UK harm reduction monitoring.[3]
Standard urine drug screens do not detect carisoprodol specifically. Any tablet obtained outside a verified pharmacy supply chain should be treated as potentially adulterated.
Guidelines
- Verify that tablets come from a licensed pharmacy with a matching prescription. Treat any tablet from an unverified source as potentially containing other active substances.
- Do not exceed the prescribed dose. The margin between therapeutic and dangerous blood concentrations is narrow.[5]
- Do not combine with opioids, benzodiazepines, alcohol, or GHB. Each combination increases overdose risk substantially.[6][14]
- Do not drive or operate machinery. Impairment is present even when the user feels sober.[4]
- Limit use to the shortest possible duration. Dependence can develop within weeks.[28]
- Do not stop abruptly after prolonged use. Withdrawal from carisoprodol can produce seizures and is potentially life-threatening.[25] Taper under medical supervision.
- Those of East Asian descent should be aware that CYP2C19 poor metabolizer status (15–20% prevalence) produces approximately four-fold higher drug exposure at standard doses.[18]
Set & Setting
Carisoprodol's most dangerous characteristic is delusions of sobriety — the gap between perceived and actual impairment is measurable even at the standard therapeutic dose.[4] Self-assessment of fitness to drive or operate machinery is unreliable.
A sedentary, safe environment is essential. Driving, climbing stairs, cooking, or any activity requiring coordination should be avoided for the full duration of effects. Inform someone nearby that impairment may not be visible to the person using.
Aftercare & integration. Carisoprodol's sedative effects resolve within hours, but meprobamate's longer half-life (~10 hours) means residual impairment may persist into the following day — particularly after repeated dosing. Plan for reduced coordination and slowed reaction times the morning after use.
If using as prescribed for musculoskeletal pain, monitor whether the same dose continues to provide relief. Diminishing effectiveness within the first two weeks is an early signal of tolerance and should prompt a conversation with the prescribing clinician rather than dose escalation.
Recovery & Support
Carisoprodol dependence shares characteristics with barbiturate and benzodiazepine dependence. Withdrawal is potentially life-threatening and must not be attempted without medical supervision.[25] A supervised taper, typically using benzodiazepines, is the standard approach.
Because carisoprodol abuse frequently co-occurs with opioid and benzodiazepine use,[11] recovery planning should address all concurrent substance use. Support resources include SAMHSA's National Helpline (1-800-662-4357), local addiction medicine services, and mutual aid groups familiar with sedative-hypnotic dependence.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Slow, shallow, or stopped breathing
- Blue or grey lips or fingertips
- Unresponsiveness or inability to be roused
- Seizures
- Hyperreflexia, muscle rigidity, or involuntary jerking (may indicate serotonin syndrome[7])
Immediate steps:
- Call emergency services immediately if breathing is slow, irregular, or absent.
- Place the person in the recovery position (on their side) to prevent choking.
- Monitor breathing continuously until help arrives.
- Do not induce vomiting.
- Do not leave the person alone.
What to tell the dispatcher:
- The substance taken (carisoprodol / Soma), the amount if known, and the time of ingestion.
- Any other substances taken — especially opioids, benzodiazepines, or alcohol.
- Current symptoms: breathing rate, responsiveness, any seizure activity or muscle rigidity.
- Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
Carisoprodol's legal status has tightened progressively over six decades, driven by accumulating evidence of abuse, dependence, and fatal overdose.[3]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule IV (Controlled Substances Act) | DEA final rule published 12 December 2011; effective 11 January 2012[13] |
| European Union | Marketing authorization withdrawn | Withdrawn 2008; no longer available through standard prescription[12] |
| Norway | Highest scheduling; market withdrawal | Rescheduled 1 August 2007; market withdrawal 1 May 2008. Post-withdrawal surveillance confirmed reduced harms[12] |
| United Kingdom | Not currently controlled under MDA 1971; ACMD recommending Class C, Schedule 4 | ACMD report 2025; UN Convention obligation pending domestic implementation[3] |
| Canada | Schedule V controlled substance | Removed from Prescription Drug List; reclassified as of 14 April 2025citation needed |
| Australia | Not on Australian Register of Therapeutic Goods | Accessible via Special Access Scheme onlycitation needed |
| South Korea | Controlled substance | Controls implemented following documented abuse and fatalities[29] |
| Sweden | Market withdrawal | Withdrawn 1994citation needed |
| India | Available in some states; no national scheduling | Documented abuse, particularly in North India[26] |
| International | UN Convention on Psychotropic Substances, Schedule IV | CND Decision 68/6, 2025[3] |
Street-level availability in the UK has been documented through "red apple" formulations combining carisoprodol with tapentadol, identified through harm reduction monitoring.[3] Standard urine immunoassays do not screen for carisoprodol; confirmation requires specialized laboratory methods.
references
- [1]
- [2] ^abcBerger F, Kletzkin M, Ludwig B, Margolin S (1960) THE HISTORY, CHEMISTRY, AND PHARMACOLOGY OF CARISOPRODOL — Annals of the New York Academy of Sciences doi:10.1111/j.1749-6632.1960.tb42792.x
- [3]
- [4]
- [5] ^abcMcIntyre IM, Sherrard J, Lucas J (2012) Postmortem carisoprodol and meprobamate concentrations in blood and liver: lack of significant redistribution — Journal of Analytical Toxicology doi:10.1093/jat/bks011
- [6]